tiprankstipranks
Prothena (PRTA)
NASDAQ:PRTA
US Market
PRTA
Prothena
RESEARCH TOOLSreports
Want to see PRTA full AI Analyst Report?

Prothena (PRTA) Stock Forecast & Price Target

679 Followers
See the Price Targets and Ratings of:

PRTA Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
3 Buy
1 Hold
1 Sell
Based on 5 analysts giving stock ratings to
Prothena
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRTA Stock 12 Month Forecast

Average Price Target

$21.40
▲(96.33% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $21.40 with a high forecast of $36.00 and a low forecast of $8.00. The average price target represents a 96.33% change from the last price of $10.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","20":"$20","37":"$37","11.5":"$11.5","28.5":"$28.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11.5,20,28.5,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.64,12.590769230769231,14.541538461538462,16.492307692307694,18.443076923076923,20.393846153846155,22.344615384615388,24.295384615384616,26.246153846153845,28.196923076923078,30.14769230769231,32.098461538461535,34.049230769230775,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.64,11.467692307692309,12.295384615384616,13.123076923076923,13.95076923076923,14.778461538461539,15.606153846153845,16.433846153846154,17.26153846153846,18.089230769230767,18.916923076923077,19.744615384615383,20.57230769230769,{"y":21.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.64,10.436923076923078,10.233846153846155,10.03076923076923,9.827692307692308,9.624615384615385,9.421538461538463,9.218461538461538,9.015384615384615,8.812307692307693,8.60923076923077,8.406153846153845,8.203076923076923,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.03,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.64,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$36.00Average Price Target$21.40Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on PRTA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$36
Buy
230.28%
Upside
Reiterated
05/08/26
Piper Sandler Sticks to Its Buy Rating for Prothena (PRTA)
H.C. Wainwright Analyst forecast on PRTA
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$30
Buy
175.23%
Upside
Reiterated
05/08/26
Analyst Reiterates Buy on Prothena, Maintaining $30 Price Target on CYTOPE and PRX012-TfR Platform Strength
Citizens JMP Analyst forecast on PRTA
Jason Butler
Citizens JMP
Citizens JMP
$19→$20
Buy
83.49%
Upside
Reiterated
05/08/26
Prothena price target raised to $20 from $19 at CitizensProthena price target raised to $20 from $19 at Citizens
RBC Capital Analyst forecast on PRTA
Brian Abrahams
RBC Capital
RBC Capital
$12→$13
Hold
19.27%
Upside
Reiterated
05/08/26
Prothena (PRTA) Gets a Hold from RBC Capital
Bank of America Securities Analyst forecast on PRTA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$8
Sell
-26.61%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (NASDAQ: AARD), Prothena (NASDAQ: PRTA) and Eli Lilly & Co (NYSE: LLY)
Wolfe Research Analyst forecast on PRTA
Rudy Li
Wolfe Research
Wolfe Research
$18
Buy
65.14%
Upside
Initiated
12/31/25
Chardan Capital Initiates a Buy Rating on Prothena (PRTA)
Cantor Fitzgerald Analyst forecast on PRTA
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Reiterated
06/20/25
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)
Oppenheimer Analyst forecast on PRTA
Jay Olson
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
06/16/25
Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)
UBS Analyst forecast on PRTA
Michael Yee
UBS
UBS
$32→$6
Hold
-44.95%
Downside
Downgraded
05/27/25
Prothena's Hold Rating: Clinical Trial Challenges and Financial Pressures
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on PRTA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$36
Buy
230.28%
Upside
Reiterated
05/08/26
Piper Sandler Sticks to Its Buy Rating for Prothena (PRTA)
H.C. Wainwright Analyst forecast on PRTA
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$30
Buy
175.23%
Upside
Reiterated
05/08/26
Analyst Reiterates Buy on Prothena, Maintaining $30 Price Target on CYTOPE and PRX012-TfR Platform Strength
Citizens JMP Analyst forecast on PRTA
Jason Butler
Citizens JMP
Citizens JMP
$19→$20
Buy
83.49%
Upside
Reiterated
05/08/26
Prothena price target raised to $20 from $19 at CitizensProthena price target raised to $20 from $19 at Citizens
RBC Capital Analyst forecast on PRTA
Brian Abrahams
RBC Capital
RBC Capital
$12→$13
Hold
19.27%
Upside
Reiterated
05/08/26
Prothena (PRTA) Gets a Hold from RBC Capital
Bank of America Securities Analyst forecast on PRTA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$8
Sell
-26.61%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (NASDAQ: AARD), Prothena (NASDAQ: PRTA) and Eli Lilly & Co (NYSE: LLY)
Wolfe Research Analyst forecast on PRTA
Rudy Li
Wolfe Research
Wolfe Research
$18
Buy
65.14%
Upside
Initiated
12/31/25
Chardan Capital Initiates a Buy Rating on Prothena (PRTA)
Cantor Fitzgerald Analyst forecast on PRTA
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Reiterated
06/20/25
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)
Oppenheimer Analyst forecast on PRTA
Jay Olson
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
06/16/25
Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)
UBS Analyst forecast on PRTA
Michael Yee
UBS
UBS
$32→$6
Hold
-44.95%
Downside
Downgraded
05/27/25
Prothena's Hold Rating: Clinical Trial Challenges and Financial Pressures
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Prothena

3 Months
Jason ButlerCitizens JMP
Success Rate
8/24 ratings generated profit
33%
Average Return
-5.33%
Copying Jason Butler's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -5.33% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
4/17 ratings generated profit
24%
Average Return
-22.91%
Copying Andrew Fein's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -22.91% per trade.
2 Years
Andrew FeinH.C. Wainwright
Success Rate
4/17 ratings generated profit
24%
Average Return
-24.46%
Copying Andrew Fein's trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -24.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRTA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
9
5
4
4
5
Buy
0
0
0
0
0
Hold
1
1
1
1
1
Sell
1
0
1
1
2
Strong Sell
0
0
0
0
0
total
11
6
6
6
8
In the current month, PRTA has received 5 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. PRTA average Analyst price target in the past 3 months is 21.40.
Each month's total comprises the sum of three months' worth of ratings.

PRTA Financial Forecast

PRTA Earnings Forecast

Next quarter’s earnings estimate for PRTA is -$0.39 with a range of -$0.45 to -$0.31. The previous quarter’s EPS was $0.60. PRTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PRTA has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRTA is -$0.39 with a range of -$0.45 to -$0.31. The previous quarter’s EPS was $0.60. PRTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PRTA has Performed in-line its overall industry.

PRTA Sales Forecast

Next quarter’s sales forecast for PRTA is $426.00K with a range of $0.00 to $1.53M. The previous quarter’s sales results were $51.08M. PRTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PRTA has Performed in-line its overall industry.
Next quarter’s sales forecast for PRTA is $426.00K with a range of $0.00 to $1.53M. The previous quarter’s sales results were $51.08M. PRTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PRTA has Performed in-line its overall industry.

PRTA Stock Forecast FAQ

What is PRTA’s average 12-month price target, according to analysts?
Based on analyst ratings, Prothena’s 12-month average price target is 21.40.
    What is PRTA’s upside potential, based on the analysts’ average price target?
    Prothena has 96.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRTA a Buy, Sell or Hold?
          Prothena has a consensus rating of Moderate Buy which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Prothena’s price target?
            The average price target for Prothena is 21.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $36.00 ,the lowest forecast is $8.00. The average price target represents 96.33% Increase from the current price of $10.9.
              What do analysts say about Prothena?
              Prothena’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of PRTA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.